Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;16(1):21-24.
doi: 10.17925/EE.2020.16.1.21. Epub 2020 Feb 4.

Pragmatic Opioid Use in Painful Diabetic Neuropathy

Affiliations
Review

Pragmatic Opioid Use in Painful Diabetic Neuropathy

Yatan Pal Singh Balhara et al. Eur Endocrinol. 2020 Apr.

Abstract

The management of painful diabetic neuropathy poses a tough clinical challenge. Although opioid analgesics are considered as second- or third-line agents in the management of moderate-to-severe neuropathic pain, prescription of opioids for this indication is higher than expected. This narrative review is a recommendation on how to ensure pragmatic use of opioids for those with painful diabetic neuropathy while avoiding complications such as opioid overdose, opioid diversion and the development of opioid-use disorder. Risk mitigation strategies at the level of the clinician include periodic assessment and documentation of clinical details, treatment history and psychosocial status. Using a multimodal approach to pain management, medication counselling, adherence monitoring programmes, evidence-based opioid dosing strategies and empowering patients to make treatment decisions are effective strategies in reducing risk associated with prolonged opioid use. At the organisational and policy level, using prescription drug monitoring programmes, carrying out periodic opioid utilisation reviews and providing training to patients and physicians on safe opioid use are useful, implementable strategies.

Keywords: Diabetes; analgesia; neuropathy; opioid abuse; opioid addiction; opioids.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Yatan Pal Singh Balhara, Shalini Singh and Sanjay Kalra have no financial or non-financial relationships or activities to declare in relation to this article. Sanjay Kalra is a member of the journal’s Editorial Board.

References

    1. World Health Organisation. Diabetes. 2018. www.who.int/news-room/fact-sheets/detail/diabetes Available at: (accessed 7 January 2020).
    1. Callaghan BC, Cheng HT, Stables CL. et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34. - PMC - PubMed
    1. Ziegler D, Rathmann W, Dickhaus T. et al. KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393–400. - PubMed
    1. Abbott CA, Malik RA, van Ross ERE. et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220–4. - PMC - PubMed
    1. Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6:15–28. - PMC - PubMed

LinkOut - more resources